Le Lézard
Classified in: Health, Science and technology, Business
Subject: CON

New Collaboration with StafaCT Will Optimize Patient Pathways for Cellular Treatments



LAKEWOOD, Colo., Feb. 24, 2018 /PRNewswire/ -- Terumo BCT announced today that it will be the exclusive distributor for Stafa Cellular Therapy (StafaCT), a U.S.-based software developer. StafaCT software supports healthcare facilities and cell labs as they manage each phase of the cellular therapy process including patient referral, cell collection and processing, transplant and follow-up. Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular technologies. 

Terumo BCT will now be the exclusive distributor for Stafa Cellular Therapy, a U.S.-based software developer.

Stem cell and immune effector cell transplants are used to treat various blood cancers, immune system disorders and genetic diseases. Given the significance of these treatments to patients, StafaCT and Sarah Cannon Blood Cancer Network co-developed software to manage each phase of the transplant process.

"Ensuring patients have access to the highest level of care throughout the transplantation process is central to our mission," said Fred LeMaistre, M.D., Senior Vice President and Physician-in-Chief of Blood Cancers, Sarah Cannon. "By implementing technologies that support improved patient outcomes and integrated communication for the entire care team, we are setting a new standard in patient care."

Terumo BCT will expand access to StafaCT software to healthcare organizations. The software meets the needs of therapeutic apheresis and cellular therapy procedures, including hematopoietic cellular transplantation and immune effector cellular therapy.

Offering StafaCT software advances Terumo BCT's ongoing support of the transplant and apheresis communities. For more than 30 years, Terumo BCT has been an innovator in therapeutic apheresis. The Specta Optia® Apheresis System and the COBE Spectra® Apheresis System are used predominantly throughout the world. Now with StafaCT, Terumo BCT can also streamline workflows and the collection and management of data throughout the continuum of care.

"Not only does the software from StafaCT ultimately benefit patients, it also helps to ensure the health of the organizations that deliver that care," says Roy Jones, M.D., Ph.D., former Chair of the Informatics Committee for the American Society for Blood and Marrow Transplantation.

About Terumo BCT
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

About Stafa Cellular Therapy
Stafa Cellular Therapy (StafaCT) is a software company that specializes in cellular therapy applications, including but not limited to blood and marrow transplants. Its suite of products covers data management, operational workflows, and compliance monitoring for the entire cellular therapy process from the initial referral to infusion and follow up. Formerly the cellular therapy product team at Velos, StafaCT was spun out into its own company in 2015.

About The Sarah Cannon Blood Cancer Network
Sarah Cannon brings together physician-led blood cancer programs across the United States and United Kingdom to offer patients convenient access to care including hematopoietic cell transplantation (HCT) and clinical trials. For more information about the Network and Sarah Cannon's full suite of oncology services, visit sarahcannon.com.

Media Contact
Corporate Communications
Phone: +1.303.542.5396
press@terumobct.com

Terumo BCT

SOURCE Terumo BCT


These press releases may also interest you

at 12:00
The "Precision Medicine Market - Forecasts from 2018 to 2023" report has been added to ResearchAndMarkets.com's offering. The precision medicine market is projected to grow at a CAGR of 8.47% to reach US$87.877 billion in 2023 from US$53.966 billion...

at 12:00
SAN DIEGO, Sept. 20, 2018 /PRNewswire-PRWeb/ -- Casa Palmera, a private rehabilitation center based in San Diego, today announces their annual alumni celebration, Benefit for Hope, which will be held on Saturday, October 6th. Casa Palmera is a...

at 12:00
LOS ANGELES, Sept. 20, 2018 /PRNewswire-PRWeb/ -- Dr. Matt Nejad, a lead dentist at an upscale dental practice in Beverly Hills, is best known for his elite training and sought-after expertise in biomimetic dentistry and cosmetic dentistry....

at 12:00
NEW YORK, Sept. 20, 2018 /PRNewswire-PRWeb/ -- Spiritual Care Association (SCA), the first multidisciplinary, international professional membership association for spiritual care providers, announced today Rabbi Miriam Berkowitz as Director of...

at 11:58
Ultimate Medical Academy's community of learning will come together on Saturday, Sept. 22 in Tampa, Florida to celebrate the graduation (#UMAgrad) of the nonprofit higher education institution's Fall class of 2018. More than 900 UMA graduates from 30...

at 11:49
Myopia is one of the most prevalent vision issues globally, especially in children. By 2050, it is estimated nearly five billion people will be myopic1 and in the U.S., 42 percent will be myopic by 2020 compared to just 28 percent in 2000.2 Essilor,...




News published on 24 february 2018 at 12:46 and distributed by: